BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 36417578)

  • 1. Tissue-Targeted Drug Delivery Strategies to Promote Antigen-Specific Immune Tolerance.
    Rui Y; Eppler HB; Yanes AA; Jewell CM
    Adv Healthc Mater; 2023 Jan; 12(6):e2202238. PubMed ID: 36417578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering Immune Tolerance with Biomaterials.
    Gammon JM; Jewell CM
    Adv Healthc Mater; 2019 Feb; 8(4):e1801419. PubMed ID: 30605264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell and biomaterial delivery strategies to induce immune tolerance.
    Scotland BL; Shaw JR; Dharmaraj S; Caprio N; Cottingham AL; Joy Martín Lasola J; Sung JJ; Pearson RM
    Adv Drug Deliv Rev; 2023 Dec; 203():115141. PubMed ID: 37980950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomaterial-based approaches to engineering immune tolerance.
    Emerson AE; Slaby EM; Hiremath SC; Weaver JD
    Biomater Sci; 2020 Dec; 8(24):7014-7032. PubMed ID: 33179649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomaterial Strategies for Selective Immune Tolerance: Advances and Gaps.
    Carey ST; Bridgeman C; Jewell CM
    Adv Sci (Weinh); 2023 Mar; 10(8):e2205105. PubMed ID: 36638260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-Assembly as a Molecular Strategy to Improve Immunotherapy.
    Froimchuk E; Carey ST; Edwards C; Jewell CM
    Acc Chem Res; 2020 Nov; 53(11):2534-2545. PubMed ID: 33074649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering tolerance using biomaterials to target and control antigen presenting cells.
    Tostanoski LH; Gosselin EA; Jewell CM
    Discov Med; 2016 May; 21(117):403-10. PubMed ID: 27355336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomaterial-Driven Immunomodulation: Cell Biology-Based Strategies to Mitigate Severe Inflammation and Sepsis.
    Lasola JJM; Kamdem H; McDaniel MW; Pearson RM
    Front Immunol; 2020; 11():1726. PubMed ID: 32849612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance.
    Kishimoto TK; Maldonado RA
    Front Immunol; 2018; 9():230. PubMed ID: 29515571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomaterials for antigen-specific immune tolerance therapy.
    Park J; Wu Y; Li Q; Choi J; Ju H; Cai Y; Lee J; Oh YK
    Drug Deliv Transl Res; 2023 Jul; 13(7):1859-1881. PubMed ID: 36094655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing the liver to induce antigen-specific immune tolerance.
    Gottwick C; Carambia A; Herkel J
    Semin Immunopathol; 2022 Jul; 44(4):475-484. PubMed ID: 35513495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin.
    Shah SA; Oakes RS; Jewell CM
    Adv Drug Deliv Rev; 2024 Jun; 209():115315. PubMed ID: 38670230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining antigen and immunomodulators: Emerging trends in antigen-specific immunotherapy for autoimmunity.
    Northrup L; Christopher MA; Sullivan BP; Berkland C
    Adv Drug Deliv Rev; 2016 Mar; 98():86-98. PubMed ID: 26546466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance.
    Pearson RM; Casey LM; Hughes KR; Miller SD; Shea LD
    Adv Drug Deliv Rev; 2017 May; 114():240-255. PubMed ID: 28414079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cationic nanoparticles-based approaches for immune tolerance induction in vivo.
    Mao K; Wang J; Xie Q; Yang YG; Shen S; Sun T; Wang J
    J Control Release; 2024 Feb; 366():425-447. PubMed ID: 38154540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tackling autoimmunity with nanomedicines.
    Feng X; Liu J; Xu W; Li G; Ding J
    Nanomedicine (Lond); 2020 Jul; 15(16):1585-1597. PubMed ID: 32669025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection.
    Coutinho A; Caramalho I; Seixas E; Demengeot J
    Curr Top Microbiol Immunol; 2005; 293():43-71. PubMed ID: 15981475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing biomaterials for the modulation of allogeneic and autoimmune responses to cellular implants in Type 1 Diabetes.
    Samojlik MM; Stabler CL
    Acta Biomater; 2021 Oct; 133():87-101. PubMed ID: 34102338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen-Specific Tolerization and Targeted Delivery as Therapeutic Strategies for Autoimmune Diseases.
    Shakya AK; Nandakumar KS
    Trends Biotechnol; 2018 Jul; 36(7):686-699. PubMed ID: 29588069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticles for Inducing Antigen-Specific T Cell Tolerance in Autoimmune Diseases.
    Benne N; Ter Braake D; Stoppelenburg AJ; Broere F
    Front Immunol; 2022; 13():864403. PubMed ID: 35392079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.